𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

✍ Scribed by Nienke M. van der Velde; Marian J.E. Mourits; Henriëtte J.G. Arts; Jacob de Vries; Beike K. Leegte; Grieteke Dijkhuis; Jan C. Oosterwijk; Geertruida H. de Bock

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
83 KB
Volume
124
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Women at high risk of ovarian cancer due to a genetic predisposition may opt for either surveillance or prophylactic bilateral salpingo‐oophorectomy (pBSO). Main objective of our study was to determine the effectiveness of ovarian cancer screening in women with a BRCA1/2 mutation. We evaluated 241 consecutive women with a BRCA1 or BRCA2 mutation who were enrolled in the surveillance program for hereditary ovarian cancer from September 1995 until May 2006 at the University Medical Center Groningen (UMCG), The Netherlands. The ovarian cancer screening included annual pelvic examination, transvaginal ultrasound (TVU) and serum CA125 measurement. To evaluate the effectiveness of screening in diagnosing (early stage) ovarian cancer sensitivity, specificity, positive and negative predictive values (PPV and NPV) of pelvic examination, TVU and CA125 were calculated. Three ovarian cancers were detected during the surveillance period; 1 prevalent cancer, 1 interval cancer and 1 screen‐detected cancer, all in an advanced stage (FIGO stage IIIc). A PPV of 20% was achieved for pelvic examination, 33% for TVU and 6% for CA125 estimation alone. The NPV were 99.4% for pelvic examination, 99.5% for TVU and 99.4% for CA125. All detected ovarian cancers were in an advanced stage, and sensitivities and positive predictive values of the screening modalities are low. Restricting the analyses to incident contacts that contained all 3 screening modalities did not substantially change the outcomes. Annual gynecological screening of women with a BRCA1/2 mutation to prevent advanced stage ovarian cancer is not effective. © 2008 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Ovarian cancer susceptibility alleles an
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
✍ Susan J. Ramus; Antonis C. Antoniou; Karoline B. Kuchenbaecker; Penny Soucy; Jon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB 👁 1 views

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of

Contribution of BRCA1 and BRCA2 mutation
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
✍ Susan J. Ramus; Patricia A. Harrington; Carole Pye; Richard A. DiCioccio; Mark J 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB

A total of 283 epithelial ovarian cancer families from the United Kingdom (UK) and the United States (US) were screened for coding sequence changes and large genomic alterations (rearrangements and deletions) in the BRCA1 and BRCA2 genes. Deleterious BRCA1 mutations were identified in 104 families (

BRCA1 and BRCA2 mutations in breast/ovar
BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy
✍ L. Stuppia; P. Di Fulvio; G. Aceto; S. Pintor; S. Veschi; V. Gatta; A. Colosimo; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

We report on the screening of the entire BRCA1/BRCA2 coding sequence by SSCP, PTT, and direct sequencing in 68 Italian families with recurrent breast or ovarian cancer. For each investigated proband, the probability of being carrier of a BRCA1/BRCA2 mutation was evaluated using the BRCAPRO software.

Recurrent BRCA1 and BRCA2 germline mutat
Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: A founder mutation of BRCA1 identified in the Chinese population
✍ Ui-Soon Khoo; Kelvin Y.K. Chan; Annie N.Y. Cheung; W.C. Xue; D.H. Shen; K.Y. Fun 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

Previous mutational analysis for BRCA gene mutations in sporadic ovarian cancer occurring in Chinese patients in Hong Kong identified six germline BRCA1 mutations and one germline BRCA2 mutation, six of which were novel (Khoo et al., 2000). Knowledge of BRCA gene mutations in the Chinese population

Prevalence of BRCA1 and BRCA2 mutations
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients
✍ Muhammad U. Rashid; Anbreen Zaidi; Diana Torres; Faisal Sultan; Axel Benner; Bil 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 312 KB 👁 2 views

## Abstract Among Asian countries, Pakistan has the highest rates of breast and ovarian cancer. To assess the contribution of the __BRCA1__ and __BRCA2__ germ line mutations to these high rates, we conducted the first study of 176 Pakistani breast and ovarian cancer patients, selected on family his

BRCA1 and BRCA2 mutation analysis in bre
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland
✍ Magdalena Perkowska; Izabela BroŻek; Barbara Wysocka; Karin Haraldsson; Therese 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

Sixty high-risk breast and/or ovarian cancer families from North-Eastern Poland were screened for germline mutations in BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185), using a combination of protein truncation test, denaturing high-performance liquid chromatography and direct sequencing. Sixteen (27%)